<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04224051</url>
  </required_header>
  <id_info>
    <org_study_id>MAAAGI</org_study_id>
    <nct_id>NCT04224051</nct_id>
  </id_info>
  <brief_title>Metformin for Abdominal Aortic Aneurysm Growth Inhibition</brief_title>
  <acronym>MAAAGI</acronym>
  <official_title>Metformin for AAA Growth Inhibition, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-centre population-based open-label randomized controlled trial with allocation&#xD;
      concealment and blinded outcome assessment will examine if up to 2g metformin daily slows AAA&#xD;
      growth in patients with small AAAs who do not have diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with no history of diabetes will be recruited from a cohort of patients with&#xD;
      diagnosed AAA and a maximum aortic diameter of 30-49mm for men and 30-44mm for women.&#xD;
&#xD;
      A total of 500 subjects with AAA will be included in the study, 250 in each study arm.&#xD;
      Patients will be randomised to metformin or standard care in a 1:1 ratio.&#xD;
&#xD;
      CT imaging and AAA US will be performed at baseline, 24 months and end of study, as well as&#xD;
      if necessary according to clinical routine. Study drug will start at baseline and continue&#xD;
      through completion.&#xD;
&#xD;
      When all enrolled subjects have completed the 24-month follow-up (including imaging) an&#xD;
      interim analysis will be performed to assess for efficacy and safety; if there is no trend&#xD;
      towards a positive effect or signs of a harmful effect of metformin, the study will be&#xD;
      stopped at this phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal aortic aneurysm (AAA) diameter growth rate</measure>
    <time_frame>5 years</time_frame>
    <description>To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA diameter (mm) in patients with small AAAs who do not have diabetes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal aortic aneurysm (AAA) volume growth rate</measure>
    <time_frame>5 years</time_frame>
    <description>To examine if up to 2g metformin administered daily over a five-year period slows AAA growth measured as computed tomography (CT) imaging assessed AAA volume (ml) in patients with small AAAs who do not have diabetes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Abdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Metformin target dose of 2g daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablets taken orally with target dose of 2g daily plus standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care includes help with smoking cessation if applicable; encouragement of physical activity and a healthy diet; blood pressure control; statin and anti-platelet therapy treatment if the patient have clinical manifestations of atherosclerotic disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin target dose 2 g daily</description>
    <arm_group_label>Metformin target dose of 2g daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Abdominal aortic aneurysm surveillance</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written informed consent.&#xD;
&#xD;
          2. Male and female patients.&#xD;
&#xD;
          3. Age 50-80 years.&#xD;
&#xD;
          4. Documented AAA Ø 30-49 mm for men and 30-44 mm for women.&#xD;
&#xD;
          5. Fasting p-glucose &lt;7.0 mmol/L. Fasting is defined as no caloric intake for ≥8 h.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Short expected survival.&#xD;
&#xD;
          2. History of current or previous diabetes mellitus.&#xD;
&#xD;
          3. Current or previous use of metformin.&#xD;
&#xD;
          4. Not expected to tolerate metformin.&#xD;
&#xD;
          5. Contraindications to metformin treatment according to SmPC&#xD;
&#xD;
          6. Known or suspected connective tissue disorder (Marfans syndrome, etc), infected or&#xD;
             inflammatory aneurysm, aneurysm development after aortic dissection or previous&#xD;
             surgery of the infrarenal aorta.&#xD;
&#xD;
          7. Enrollment in either another investigational drug or medical device study or another&#xD;
             investigational study of an approved drug or medical device within 30 days prior to&#xD;
             enrollment of the current study.&#xD;
&#xD;
          8. If, in the opinion of the investigator, it is not in the patient's medical interest to&#xD;
             participate in the study or the patient is unlikely to be able to comply with the&#xD;
             study protocol.&#xD;
&#xD;
          9. Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Unosson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <state>Sverige</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Jon Unosson</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT04224051/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

